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Guest Editorial
Drug Eluting Stent: A Major Advance in Fighting Coronary Artery
Restenosis
YUK-KONG LAU
From Department of Medicine, Ruttonjee and Tang Shiu Kin Hospitals, Hong Kong
Since the first use of coronary angioplasty in 1977,
there have been major growth and development in
percutaneous coronary intervention (PCI). Due to the
advances in techniques, experiences, devices, and newer
potent antiplatelet and antithrombotic medications, PCI
is increasingly performed in highly complex and highrisk patients with a reasonably low complication rate.
Coupled with reduced discomfort, shorter hospital stay
and recovery time, it has far outnumbered the volume
of coronary artery bypass surgery. Currently, 1.7 million
PCI procedures are performed annually worldwide with
increases by 15-20% per year the last decade.
Problems in the early years of balloon angioplasty
included dissection, abrupt closure and restenosis,
the first two of which are largely controlled by
coronary stenting since early 1990's. Moreover, stents
significantly reduce coronary artery restenosis from an
average of 30-50% post balloon angioplasty to 20-30%
after stenting. Thus, stents improve the short-term
success rate and the safety of PCI. In longer term, they
decrease the restenosis and the need for repeat
revascularization. As a major breakthrough in PCI, stents
are currently widely used in about 80% of such
procedures.
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However, stenting does not eliminate restenosis.
The three major pathogenic factors in restenosis are
elastic recoil, negative arterial remodeling and
neointimal hyperplasia. Stents virtually eliminate elastic
recoil and counteract the arterial remodeling. But
neointimal hyperplasia after stenting can still cause
significant and refractory restenosis. Depending on the
pattern of in-stent restenosis, treatment with balloon
angioplasty alone is still followed by a further restenosis
in 45-55% of cases. Intravascular brachytherapy has
been used in recent years and found to be effective in
managing in-stent restenosis, but the recurrence after
brachytherapy is still in the order of 26-32%. 1-3
Moreover, the procedure itself adds extra cost, and
technical difficulty and consumes extra procedure time.
The long-term safety with the extra radiation is still
uncertain and meritorious of concern. Thus, to prevent
the development of restenosis right after PCI is a critical
issue. Enormous amount of research is being conducted
to achieve this ideal goal.
The process of neointimal hyperplasia is initiated
from the arterial injury sustained during PCI. The arterial
injury and intimal denudation trigger off inflammatory
responses. Growth factors and cytokines produced would
activate smooth muscle cell (SMC) proliferation and
migration and elicit production of extracellular matrix.
Together these processes significantly limit intra-arterial
lumen leading to restenosis. Stent-based drug delivery
to intervene this process has been developed in an
attempt to counteract this phenomenon. A number of
drugs have been studied and additional ones are being
pursued at present: anticoagulants (heparin, hirudin),
antiplatelet agents (abciximab), anti-inflammatory
drugs (dexamethasone), and antiproliferative agents
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(sirolimus, paclitaxel, actinomycin D and batimastat).
To date, the sirolimus-eluting stents appear to
demonstrate a remarkable efficacy and safety in
preventing restenosis.
Sirolimus is the generic name of Rapamycin, a
drug used in preventing renal transplant rejection. Food
and Drug Administration (FDA) in the USA had
approved this clinical use in 1999 and CE Mark in
Europe was obtained in 2000. Sirolimus is a cytostatic
agent, by virtue of cell cycle inhibition which suppresses
SMC proliferation and inflammatory cell activity. A
small fractional amount of systemtic dose of sirolimus
is incorporated into a polymer matrix surrounding a
balloon-expandable metallic stent (Bx Velocity, Cordis,
Johnson & Johnson). In vivo, the drug is released slowly
and gradually over 30 to 45 days after deployment in
the coronary artery.
The First-In-Man (FIM) study4 was a small pilot
trial involving 45 patients with de novo coronary lesions
of length <18 mm and vessel diameter 3.0-3.5 mm. All
patients were treated with an 18 mm long sirolimuseluting stent. Follow-up to 24 months revealed 0% instent restenosis and minimal neointimal hyperplasia.
There was no subacute or late stent thrombosis. Only
one patient required another PTCA at 14th month due
to new progression at a site outside the previously stented
segment.
A RAndomized double-blind study with the
sirolimus-eluting Bx VElocity balloon expandable
stent in the treatment of patients with de novo native
coronary artery Leision (RAVEL) 5 involved 238
patients from 19 centers. One hundred and twenty
patients received the sirolimus-eluting stents while
118 patients received the bare stents as control. At 6
months, there was 0% restenosis rate in the sirolimus
arm as opposed to 26% in the control arm (p<0.0001).
At 12 months, target lesion revascularization (TLR)
rate was 0% in the sirolimus group. There was no
difference in death rate and myocardial infarction
(MI) but the major adverse cardiac event (MACE)
rate was 5.8% in the sirolimus group versus 28.8%
in the control arm (p<0.0001), mainly due to the 27%
TLR rate in the latter.
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Subsequently, the results of a multicenter,
randomized double blind study of the SIRolImUScoated Bx Velocity balloon expandable stent in the
treatment of patients with de novo coronary artery
leisions (SIRIUS-400),6 were presented in May 2002.
SIRIUS involved over 1,100 patients from 53 sites in
the U.S. with half of whom received sirolimus stents.
All received 3 months of dual antiplatelet therapy
(aspirin and clopidrogrel). The patient cohort was more
complex than in RAVEL: 28% diabetes, 72%
hyperlipidemia, 42% multivessel disease, 24% Type C
lesions and 100% with a longer lesion length of 15 mm30 mm. The primary endpoint was Target Vessel Failure
(TVF: cardiac death, MI or TVR) at 9 months.
Preliminary findings of the first 400 patients showed
that the 8-months in-stent restenosis rate as assessed by
protocol-based reangiogram was reduced from 31% in
the control arm to 2% in the treated arm (p<0.001).
Independently, intravascular ultrasound confirmed a
94% reduction in neointimal hyperplasia in the sirolimus
group, as compared with control. The in-lesion (defined
as in-stent plus 5 mm proximal and distal to the stent
margin) restenosis decreased from 32.3% in the control
group to 9.2% in the sirolimus group (p<0.001). Target
lesion revascularization was reduced from 16.7% in the
control to 4.7% in the sirolimus group (a 72% reduction).
At 9-months follow-up, the event-free (from death, MI,
CABG and Re-PTCA) survival was 90.8% in the
sirolimus group versus 80.6% in the control (p=0.001).
There was no acute, subacute or late stent thrombosis in
the treatment group.
Though long-term safety beyond 2 years is still
pending, the data obtained in the last few years are
encouraging enough by the demonstrated superiority of
the sirolimus-eluting stents in significantly reducing
coronary artery restenosis and TLR. Such stent has been
approved by CE Mark in April and is available for use
in Hong Kong since May 2002.
There are other ongoing trials using sirolimuseluting stents. The E-SIRIUS trial involves 350 patients
in Europe. The C-SIRIUS trial involves 100 patients in
Canada. Another coronary bifurcation trial on 75 patients
will be completed later this year.
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However, the cost of the sirolimus-eluting stent
is substantially higher than its bare stent counterpart
by more than ten thousand Hong Kong dollars
(~US$1,300). Despite the higher initial cost, such stents
can markedly reduce the need of repeated
revascularization procedure (and potential
complications). Cost-effectiveness analysis based on
more clinical data and local patient demographics is
needed before any definite recommendation can be
made. It is likely that two groups of patients will benefit
most from using the drug eluting stents: patients with
high risk of coronary artery restenosis like diabetes,
small coronary vessel and long diffuse lesion; and
patients with high clinical risk due to restenosis such as
those with poor ventricular function and artery supplying
a large proportion of remaining viable myocardium.
Meanwhile, cardiologists should exercise clinical
judgement in individual situation and should refrain
from routine widespread use of sirolimus-eluting stents
until further health economic data of such stent are
available.
In summary, sirolimus-eluting stents represent a
major advance in our battle against coronary artery
restenosis. They will likely alter the use and approach
of PCI in managing a major cause of death in developed

J HK Coll Cardiol, Vol 10

countries including Hong Kong. Nevertheless, primary
and secondary prevention with healthy life style, exercise
and low cholesterol diet and control of smoking,
hyperlipidemia, diabetes, as well as hypertension should
be the fundamental strategy in fighting against coronary
artery disease.
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Carotid Stent-Supported Angioplasty Using Different Distal Protection
Devices
STEVEN SIU-LUNG LI, YUI-CHI SO, CHIU-LAI FU, CHEUK-HON WONG, CHIU-WAH LAM, SIU-FUNG
YIU, CHUNG-SEUNG CHIANG, KAU-CHUNG HO
From Division of Cardiology, Department of Medicine, Queen Elizabeth Hospital, Kowloon, Hong Kong
LI ET AL.: Carotid Stent-Supported Angioplasty Using Different Distal Protection Devices. Stroke is an important
cause of morbidity and mortality in Hong Kong. Extra-cranial carotid stenosis is a common cause of thrombotic
stroke, although its incidence is less in Chinese compared with Caucasians. Carotid endarterectomy is the conventional
revascularization procedure for carotid stenosis. In the past decade, carotid angioplasty has been emerging as a
treatment option for patients with significant carotid stenosis. Due to the intrinsic mechanism of angioplasty, distal
embolization causing thromboembolic stroke has been one of the most important complications of carotid stenosis.
Distal protection has been shown to be safe and effective in preventing distal embolization during the procedure.
According to their mechanism, distal protection devices can be categorized into two major types, namely distal
occlusion balloon and filters. Distal occlusion balloon system is of lower crossing profile but it causes temporary
cessation of blood flow during the procedure, which may not be well tolerated in all patients. Filters, on the other
hand, allow continuous blood flow during the procedure but are of much higher crossing profile, which may make
their passage through tight and angulated lesions difficult and traumatic. The choice of the different distal protection
devices depends on the characteristics of the lesions and the status of contralateral carotid artery and collateral
supply. Local experience reported similar feasibility and efficacy as in the literature. Although the ideal distal
protection device is yet to be developed, the use of distal protection devices would become, wherever feasible, a
standard during carotid stent-supported angioplasty. (J HK Coll Cardiol 2002;10:179-183)
Carotid angioplasty, carotid stenosis, distal cerebral protection
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Stroke is an important cause of morbidity and
mortality in Hong Kong. Extra-cranial carotid stenosis
is a common cause of thrombotic stroke. The therapy
of carotid stenosis may be either medical or
revascularizational. Carotid endarterectomy is the gold
standard of surgical revascularization of carotid stenosis
and has been shown to be superior to medical therapy
by several large randomized trials.1-3 However, in the
recent few years, with more and more published data
regarding its efficacy and safety, carotid stenosis has
been emerging as a treatment option for the treatment
of carotid stenosis.4-7
Due to the intrinsic mechanism of angioplasty,
distal embolization is an inevitable phenomenon. Plaque
disruption may occur during engagement of guiding
catheter, wire and balloon passage, balloon expansion
and stent deployment at the site of atherosclerotic lesion.
The clinical significance of the generation of embolic
particles depends on the number released and the size
of the particles. Ohki demonstrated in his ex-vivo model
that echolucent plaques and plaques with a degree of
stenosis greater than 90% produced a higher number of
embolic particles.8
There may be a number of ways to minimize the
cerebral embolization during carotid angioplasty.
Premedication with aspirin and Clopidogrel is
important. Selection of patients is also important.
Advanced age, lesion severity, long or multiple stenoses
are independent predictors of procedural stroke and are
associated with increased risk of stroke. 9 Proper
technique during the angioplasty procedure with the
least traumatic way to engage the guiding catheter and
to cross the lesion with low profile wires and balloons
should minimize the risks of distal embolization.
Finally, cerebral distal protection devices should
mechanically catch the maximal number of embolic
particles released.

The ideal protection device should be simple and
easy to use, and yet low profile and atraumatic. It should
effectively eliminate embolic particles and be well
tolerated without any cerebral ischemic phenomenon.
The current commonly available distal protection
systems may be divided into two main categories,
namely the occlusion balloon system and filters. The
distal occlusion balloon system occludes the internal
carotid artery above the lesion with the balloon inflated
at 1-2 atmosphere. The debris released by the dilatation
and stent placement is then eliminated by aspiration.
Filters, on the other hand, trap dislodged particles
without interrupting the blood flow to the distal vascular
bed.
Currently, the occlusion balloon systems include
the PercuSurge Guardwire system (Medtronic, USA)
and the PARODI system (ArteriA Medical Science, Inc)
whereas the filters include the Angioguard (Cordis,
USA), NeuroShield (Mednova, UK) and EPI (Boston
Scientific Cooperation, USA) filter systems (Table 1).
The PercuSurge GuardWire distal protection
system (Figures 1a and 1b) composed of three major
components: the GuardWire temporary occlusion
balloon, the inflation/deflation kit (consisting of the
Microseal Adaptor and EZ Flator) and the Export
Aspiration Catheter. The GuardWire has a dual role by
acting as a primary angioplasty wire and the temporary
occlusion balloon. It has a crossing profile of 0.014" at
its tip and 0.036" at the site of un-inflated occlusion
balloon. The wire itself has a 2.5 cm shapeable tip and
a working length of 200 and 300 cm. The distal
occlusion balloon has a working length of 4.5 mm and
an inflatable diameter range of 3.0 to 6.0 mm. The
Export Aspiration catheter has a working length of 145
cm with a rapid exchange design and an aspiration
lumen of 1 mm.
During the intervention procedure, the Guardwire

Table 1. Comparison of different distal protection devices
Wire
Shapeable tip length (cm)
Length of wire(cm)
Crossing profile
Sizes of devices (mm)
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GuardWire Plus
0.014"
2.5
300
0.036" at balloon site
3.0-6.0 mm inflatable range

Angioguard XP
0.014"
3.5
300
3.2-3.9 F
4-8
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NeuroShield
0.014" with a 0.018" tip
3
300
3.5 F
4-6

EPI Filter Wire
0.014"
3
300
3.9 F
3.5-5.5
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is first advanced carefully beyond the lesion. The distal
occlusion balloon is then inflated to a size about 0.5
mm larger than the reference vessel diameter. When
the balloon is optimally inflated, it becomes square
shaped and complete occlusion is confirmed by a test
of contrast injection. With the occlusion balloon
inflated, the lesion is pre-dilated, stented and postdilated as usual. Due to the presence of vertebrae as
bony landmarks, positioning of the balloon and stent
without contrast injection is rarely a problem. Aspiration
is then performed with the Export catheter.
The occlusion balloon is then deflated and flow is
restored.
The PARODI system is a 'flow reversal' system.
It consists of two units: one is a small balloon catheter
that is used to occlude the external carotid artery; the
other is a large sheath that is used to occlude the
common carotid artery. Reverse flow is established by
connecting the arterial sheath with a venous sheath
placed into the femoral vein. Any debris generated
during the angioplasty procedure would be directed
away from the cerebral circulation. A filter located in
the arteriovenous shunt prevents embolic particles to
enter the venous system.
The filters in general consist of a basket or netshaped device mounted or delivered on a steerable
0.014" wire. The filters have a porous membrane that
can block the passage of particles greater than 80
microns or above, while allowing blood to pass through.

The device is delivered across the lesion within a
delivery sheath. For tight lesions, they may be first predilated with a 2.5 mm balloon. When positioned at the
desired distal site, the delivery sheath is withdrawn and
the filter is released in a self-expanding manner. The
angioplasty procedure is then proceeded as usual with
the filter protection. After the angioplasty procedure,
the filter is then withdrawn with a capture sheath with
all the debris retrieved within the device. Angioguard
XP (Figure 1c) has a crossing profile from 3.2 to 3.9 F
(depending on the size of the filter which ranges from
4-8 mm) and can be used to treat vessels of diameters
ranging from 3-7 mm. The filter basket with 100-micron
pores is mounted on a 0.014" wire, which has a 3.5 cm
shapeable tip. The Mednova III NeuroShield (Figure 1d)
device uses a floating filter on a bare wire design that
has a 3 cm long 0.018" shapeable wire tip and a 0.014"
wire shaft. The delivery catheter has a catheter profile
of 3 F and a crossing profile of 3.5 F. The filter diameters
range from 4.0 to 6.0 mm and are compatible for vessel
sizes of 3.5 to 6.2 mm diameters. The EPI Filter Wire
(Figure 1e) has a crossing profile of 3.9 F and has a
one-size-fits-all and monorail design that can treat
vessels from 3.5 to 5.5 mm. The filter consists of a 1.5
cm long polyurethane membrane basket with 80-100
micron pores, which is mounted on a 0.014" wire with
a 3 cm long shapeable tip.
Due to the different mechanism of protection, the
choice of the distal protection devices depends very

Figures 1a and 1b. GuardWire Plus system.
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Figure 1c. Angioguard XP.

Figure 1d. NeuroShield.

Figure 1e. EPI Filter Wire.
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much on the lesion characteristics, status of collateral
circulation and the experience of the operator. Due to
its smaller crossing profile, the PercuSurge Guardwire
system is useful in crossing tight, tortuous, long or
angulated lesions. However, since the mechanism of
protection involves temporary cessation of blood flow
during the procedure, it should be avoided in patients
with contralateral carotid artery stenosis or occlusion,
or when the collateral blood supply through the circle
of Willis is deemed inadequate. On the other hand, the
filters allow antegrade blood flow during the procedure;
they are not contraindicated even in patients with
contralateral carotid artery occlusion. Nevertheless, due
to their higher crossing profile (>3 F), the filters may
not be indicated in those tight or angulated lesions or
tortuous blood vessels because forceful passage of the
device itself through the stenosis may cause significant
local disruption to the plaque, which may in turn, induce
dissection or distal embolization.
With the favorable results of distal protection,10-14
the use of distal protection devices has become a routine,
wherever feasible, during carotid angioplasty at the
author's institution. From August 2000 to January 2002,
13 patients underwent carotid angioplasty at our
institution with distal protection. The age of the patients
ranged from 52-79 years (mean 69.3±8.8 years). The
reference internal carotid artery diameters, lesion length,
pre-procedural stenosis and residual stenosis were
3.15-6.0 mm (mean 4.07±0.87 mm), 10-35mm (mean
20.3±7.5 mm), 70-99% (mean 88.7 ± 9.9%) and 0-30%
(mean 11.2 ±12.5%) respectively. PercuSurge
GuardWire Plus system was used in 8 patients,
Angioguard filter was used in 2 patients, NeuroShield
filter was used in 2 patients and EPI filter wire was
used in 1 patient. All procedures were successful with
no peri-operative neurological event. No pre-dilatation
was needed in all cases with the GuardWire system and
the GuardWire was able to cross the lesion at the first
attempt in all cases. In the case using the EPI filter wire,
in view of the kinking morphology of the lesion, predilatation of lesion was done before it was crossed with
the filter. In other cases using the filters, no predilatation was done. The mean balloon occlusion time
in the cases using the GuardWire system was 10.2
minutes. In those patients undergoing the distal
protection of the GuardWire Plus system, one patient
could not tolerate the distal protection balloon occlusion
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and early deflation of the occlusion balloon was needed.
Another patient suffered from acute stent thrombosis,
which was successfully treated with abciximab. No perioperative neurological event was observed. At 30 days
after the procedures, no neurological event or procedure
related death was observed. No local injury to the distal
vessel was observed apart from some reversible local
spasm in three cases (one with Angioguard, one with
NeuroShield and one with GuardWire Plus system). In
all cases, macroscopically visible debris was retrieved
from the protective devices, but the amount was only
mild in all cases.
Although the distal protection devices have
undergone repeated improvement and miniaturization,
the ideal device is yet to be developed. We are still
waiting for a device that has the best characteristics of
the currently available systems, i.e. having the low
profile of the distal occlusion balloon while allowing
continuous blood flow as in the filters. While proper
selection of patients and matching of the devices to
different lesions would minimize the distal embolization
phenomenon, no current distal protection device may
safely protect, for example, a long, irregular and
angulated 99% stenosis with contralateral carotid
occlusion. Though effective in preventing distal
embolization, distal protective devices are costly and
are marketed at the price of the stents. Although further
studies on the health-economics of these devices are
needed before we can draw any conclusion on their costeffectiveness, the decrease in the incidence of major
stroke during carotid angioplasty as shown in many
published series might already make their cost justified.
In conclusion, distal embolization is the most
important complication of carotid angioplasty. Distal
protection devices have been shown to reduce the distal
embolization phenomenon. Although the ideal
protection device is yet to be developed, the currently
available protective devices appear to be useful adjunct
in carotid angioplasty.
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Left Cardiac Sympathetic Denervation via Thoracoscope to Treat
Long QT Syndrome
DAYI HU1, CUILAN LI1, JUN WANG2, LEXIN WANG3, CHIEN-CHIH LIN4, WENLING LIU1, JIANFENG LI2,
ZHIMING LI1, LEI LI1
From 1Department of Cardiology, 2Department of Thoracic Surgery, the People's Hospital of Peking University,
Beijing 100044, China; 3School of Biomedical Sciences, Charles Sturt University, Australia; 4The Surgical Department
of Tainan Municipal Hospital, Tainan, Taiwan
HU ET AL.: Left Cardiac Sympathetic Denervation via Thoracoscope to Treat Long QT Syndrome. Purpose: Long
QT syndrome (LQTS) is a cardiovascular disorder characterized by prolongation of the QT interval on ECG and
presence of syncope, seizures, and sudden cardiac death. The therapy for LQTS is mainly dependent on medicines.
The aim of the present study was to investigate the feasibility and efficacy of a new surgical method of cardiac
sympathectomy for LQTS patients. Methods: Left cardiac sympathetic denervation (LCSD) were conducted on 4
LQTS patients who were resistant to β-blockers. Patients' ECG and clinical symptoms were assessed before and
after the surgery. Results: LCSD was successful in all patients. QTc decreased from 0.54±0.08 to 0.51±0.06s
immediately after the procedure. However the shortened QTc returned to prior surgery level in one patient within 24
hours of the surgery. Before LCSD, horizontal bike exercise induced a significant change in T wave amplitude and
prolongation in QTc. These changes diminished following LCSD. After 5-month follow-up, one patient who had
frequent syncopal attacks before LCSD experienced 2 episodes of transient syncope. No syncope was reported by
other patients. Conclusions: LCSD is a safe and effective therapy for LQTS resistant to β-blockers. These results
may have significant implications in patients of developing countries like China, where expensive therapies such as
implantable cardioverter defibrillator are unlikely to be widely applied due to financial constraints of the patients.
(J HK Coll Cardiol 2002;10:184-190)
Corrected QT interval, Holter monitoring ECG, horizontal bike exercise test, left cardiac sympathetic denervation,
long QT syndrome(LQTS)
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Introduction

pacemaker or an implantable cardioverter defibrillator,
even when this choice may not be the best choice for
many patients. 1 The present work summarized the
immediate and follow up results of LCSD via
thoracoscopy in 4 Chinese patients who were resistant
to β-blockers.

The long QT syndrome (LQTS) is a
cardiovascular disorder characterized by prolongation
of the QT interval on ECG and presence of syncope,
seizures, and sudden cardiac death.1 According to the
latest epidemiological data, the incidence for LQTS is
around 1 of 5000-70002 and the mortality in untreated
symptomatic patients is about 70%.1,3 The young age
of most patients and the high mortality in untreated
symptomatic patients stress the importance of
development of effective therapies.
LQTS is a genetic disease with 5 genes being
identified to be responsible for its occurrence.4 The
major mode of treatment is still medications in most
patients. β-blockers have been proven effective in
preventing syncope in 75-80% of LQTS patients,3,5 but
more than 20% of patients continue to have syncopal
episodes and remain at high risk for sudden cardiac
death despite full-dose β-blockers. Experimental and
clinical studies have suggested that left cardiac
sympathetic denervation (LCSD) may be useful for
preventing cardiac events associated with LQTS.3
However, despite its relative simplicity, LCSD is still
not widely performed in many high-risk patients
partially because the physicians, or the thoracic surgeons
in their hospitals, are not familiar with the procedure.
The consequence is that too often, the choice goes to
what appears to be the easiest approach, such as a

Methods
Patient Selection
We currently have a total of 93 LQTS patients
from 38 families under our care for more than 2 years.
Among these patients 4 were selected for LCSD due to
frequent syncope refractory to large dose of β-blockers.
Patients' clinical presentation is listed in Table 1.

Surgical Procedures
Under single-lumen tracheal incubation
anaesthesia, multiple port approach was used to enter
the pleural cavity.6 The sympathetic chain was identified
under the parietal pleura, running vertically over the
necks of the ribs in the upper costovertebral region. The
left sympathetic chain between T2 and T5 was isolated
and then clamped in one patient by titanium clamps
(Auto Suture Company, USA) to block the sympathetic
nervous truck. In other three patients the sympathetic
chain was cut after clamping. In these patients the lower

Table 1. Patients' clinical history before surgery
Sex
Age at surgery
Age at first syncope (yr)
Syncope
Cardiac arrest
Pharmacological therapy
β-blockers
β-blockers+others
Cardiac events
Rate (events/yr)
ECG parameters
Heart rate (beats/min)
QTc(s)

Case 1
F
42
32
+
–

Case 2
F
36
7
+
–

Case 3
F
44
25
+
–

Case 4
M
6
0.5
+
–

+
+

+
+

+
+

+
+

7-8

2-3

1-3

5-6

50
0.50

52
0.48

56
0.63

60
0.61

+: yes; –: no
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part of the left stellate ganglion was carefully removed.
Care was taken to resect all the anterior branches coming
off the lower part of the ganglion.

Statistical Analysis
Data were expressed as means±SD. Because
patient numbers were small, no statistical analysis was
attempted.

Non-invasive Tests
24 hour Holter monitoring electrocardiogram
(MS8000, Marqutte Company, USA) was conducted
2 days before surgery and second day after surgery. The
horizontal bike exercise test was conducted using
ergometer (EGM-II, jointly made by Yueyang
Instrument and Meter Plant of Hunan Province and First
Hospital of Peking University, China) 2 days before
and 7 days after surgery.

Results
LCSD was successful in all patients. There was
no mortality or serious complications. After the
operation, one patient developed mild Horner's
syndrome, which fully resolved in 7 days without any
specific intervention.

Alterations in QTc During the Surgery
Measurement of QT Intervals
A 12-lead ECG was obtained before general
anaesthesia. ECG was also recorded immediately before
and after LCSD. Three limb lead ECGs were
continuously monitored during the procedure.
QT interval of the body surface ECG was always
measured on lead in which the end of T wave was clear,
in most cases, on lead II or V5, sometimes on V2-V3.
The corrected QT interval (QTc) was calculated
according to the formula of Bazett (QTc = QT/RR1/2),
and reported in seconds. The RR interval was measured
during sinus rhythm, taken the mean for at least 5 beats.

The heart rate in the 4 patients remained
unchanged during or after the surgery. QTc was
shortened following the LCSD (Table 2).
The 6-year-old male patient experienced an
episode of ventricular tachycardia (TdP) and frequent
ventricular ectopics during the isolation of the
sympathetic chain. However, these arrhythmias were
terminated spontaneously (Figure 1).

QTc and Arrhythmias After the Surgery
The 24 hour Holter monitoring electrocardiogram

Table 2. The QTc alteration during surgery
Case
1
2
3
4

Before removal of ganglion
0.50
0.46
0.55
0.64

5 min after removal of ganglion
0.48
0.46
0.52
0.59

∆QTc
0.02
0
0.03
0.05

Figure 1. An episode of TdP during surgery on patient 4, a 6-year-old boy.
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showed that the mean value of QTc within 24 hours
was decreased in 3 patients to various degrees, except
that the QTc increased in one patient (Table 3). Among
the 4 patients, there was one patient (case 1) who had
frequent ventricular ectopics before surgery. After
LCSD the ventricular ectopics was decreased from
1,959 to 107 beats/24 hr, and bigeminy decreased from
1,356/24 hr to 0.

Table 3. The mean QTc comparison measured by
24 hour Holter ECG
Case
Before surgery
After surgery
QTc alteration

1
0.46
0.45
0.01

2
0.48
0.45
0.03

3
0.53
0.49
0.04

4
0.61
0.64
-0.03

Exercise Tests
The horizontal bike exercise was completed
in two patients. A 36-year-old female patient was
house bound for 6 years due to extreme anxiety
caused by syncopal attacks. She declined the
exercise test before the surgery. An after-surgery
exercise test was conducted but the protocol was
not completed due to her poor coordination. Bike
exercise test was not attempted in the 6-year-old
male patient.
In the two patients who completed the exercise
test, there was a significant change in the T wave
morphology immediately after the test, and these
changes were abolished by LCSD (Figure 2).
Before LCSD, exercise induced a greater increase
in QTc. However, there was little exercise-induced
increase in QTc after LCSD (Table 4).

Figure 2. The alteration of 12 lead ECG during horizontal bike exercise test before and after surgery. (A) shows that in case 1
exercise resulted in more T wave morphology change before surgery, the amplitude of T wave increased almost on all leads and
that after surgery the exercise nearly resulted in no change of T wave morphology. (B) shows that in case 3 exercise resulted in
more T wave morphology change before surgery, and it is manifested decrease of the amplitude of T wave and step-up of heart
rate. After surgery the amplitude of T wave and heart rate were less influenced by exercise.
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Table 4. Pre- and post-exercise QTc comparison before and after surgery
Pre
0.48
0.45

Before surgery
After surgery

Case 1 (s)
Post
∆QTc
0.54
0.06
0.46
0.01

Pre
0.62
0.63

Case 2 (s)
Post
∆QTc
0.67
0.05
0.64
0.01

Pre: data from pre-exercise; Post: data at 8 min after exercise termination; The data during exercise were not counted due to the indefinability
of T wave measurement during exercise because of noises.

Follow-up
The 4 patients were followed-up for 5 months.
Three patients remained symptom free. One patient who
had frequent (7-8 times/yr) syncopal attacks experienced
2 episodes of brief syncope 3 months after the surgery.

Discussion
This study is the first systematic assessment of
the role of LCSD in LQTS management in China. It
shows that LCSD is able to shorten QTc and reduce
syncopal attacks in most patients who have failed fulldose β-blocker therapy.

Rationale of LCSD for LQTS
Although the cause of long QT syndrome remains
unclear, abnormal cardiac sympathetic innervation and
myocardial repolarisation are believed to be responsible.7-9
T wave alternans, one of the characteristics of long QT
syndrome, can be reproduced by stimulation of the left
stellate ganglion in animals10 and in humans.11 Animal
experiments found that left stellectomy increases
ventricular fibrillation threshold whereas right
stellectomy decreases it. 12,13 In humans, left
sympathectomy normalizes the prolonged QT interval,
thereby reducing the probability of malignant
arrhythmia.3
In 1991, Schwartz et al.3 summarized the results
of 85 LQTS patients who underwent LCSD. These
patients, whose mean age at the time of surgery was 20
years, were followed for an average of 5.9 years. LCSD
significantly reduced the number of patients with cardiac
events, from 99% to 45% after the surgery. 3 It also
diminished the number of cardiac events from 22 to
1 per patient, and shortened QTc by an average of 41 ms.3

J HK Coll Cardiol, Vol 10

The 5-year survival rate in these patients was 94%.3
The results of our 4 patients who successfully
underwent LCSD are consistent with the report by
Schwartz.3 The non-invasive tools, such as 24 hour
Holter monitoring ECG and horizontal bike exercise
test used before and after surgery are very useful in
assessing the effect of LCSD. Continuous monitoring
of a 3-lead ECG during surgery showed that following
the removal or clamping of stellate ganglion and
thoracic ganglia, QTc was decreased immediately in
most patients. The QTc measured from Holter
monitoring ECG was also decreased after surgery in
most patients, indicating that this is a useful tool to
assess the effect of LCSD. The analysis of ECG during
exercise test demonstrated that LCSD attenuated the
exercise-induced changes in T wave morphology,
indicating cardiac sympathetic denervation.14

Techniques of LCSD
Left stellectomy involves ablation of the left
stellate ganglion and often produces Horner's syndrome.1
It provides only limited cardiac denervation in humans.1,3
Left cervicothoracic sympathectomy involves total left
stellectomy and removal of the first 4 or 5 thoracic
ganglia. This procedure produces an adequate cardiac
sympathetic denervation but with an associated Horner's
syndrome, resulting from interruption of the nerve fibers
directed to the ocular region that cross the upper portion
of the stellate ganglion.1 High thoracic left sympathectomy (HTLS) involves removal of the lower part of
the left stellate ganglion and the first 4 or 5 thoracic
ganglia. This procedure produces an adequate cardiac
sympathetic denervation and extremely low incidence
of Horner's syndrome because the ocular fibers are
spared.1,3 For these reasons, HTLS was used in our study
for the surgical cardiac sympathetic denervation. There
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is one patient in whom sympathetic nerve was clamped
only using titanium clamps without cutting sympathetic
nervous truck in our study. According to the QTc
alteration measured during surgery and during exercise
test before and after surgery there was no difference
between the effects of clamping and cutting. Of course,
there is a need to accumulate more data to draw the
final conclusion.
In the earlier report by Schwartz et al3 where left
stellectomy or left cervicothoracic sympathectomy was
used, there were two patients experienced chronic
hyperemia of left eye, which responded to topical
vasoconstrictor therapy. Horner's syndrome was present
in most patients early after surgery, but almost always
decreased or disappeared after surgery. In the present
study where LCSD was used, there was one patient
developed Horner's syndrome, which resolved after a
week. These results indicate that complications like
Horner's syndrome can be largely avoided via the
thoracoscopic technique.

Effects of LCSD
Although LCSD may largely reduce the
sympathetic innervation to the heart, it is unlikely to
completely abolish the influence of catecholamines to
the heart because the circulating adrenaline or
noradrenaline is not affected to a significant extent by
the procedure. Therefore the pathophysiology of
myocyte membrane ionic channels responsible for
LQTS may not be corrected completely through LCSD.
As a result, QTc is decreased, but may not return to the
normal level after LCSD. Therefore patients who
underwent successful LCSD are still advised to take βblockers for a period of time after surgery.
The study by Conrath et al15 demonstrated that
gender differences exist in response to β-adrenoceptor
blockade in patients with types 1 and 2 of LQTS. During
treatment males with LQT1 have shorter QTc interval
than females and adult patients with LQT2. Also treated
females with LQT1 exhibited less dispersion than those
with LQT2. In our study, the gender difference of QTc
shortening in response to LCSD was not seen due to
the small number of patients and lack of genotyping
data (genotyping work is in progress in our lab).
All our patients had frequent syncopal attacks
refractory to β-blockers. During a 5-month follow-up,
only one patient had a minor recurrence of symptoms
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whereas other patients remained symptom free. These
results indicate that LCSD is effective in refractory
patients in the short and media term.

Summary
This study in a small number of patients has found
that LCSD via thoracoscope is a safe and effective
method for the management of LQTS patients refractory
to conventional pharmacological therapy. LCSD
reduces QTc and prevents syncopal attacks in most
patients with no serious complications. Whether LCSD
can be used as a first choice of therapy in LQTS patients
remains to be seen.
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Use of Distal Protection Device for Percutaneous Intervention in Native
Coronary Arteries
KENNETH KA-HING LAM, SHU-KIN LI
From Cardiology Team, Department of Medicine, Pamela Youde Nethersole Eastern Hospital, Hong Kong
LAM and LI: Use of Distal Protection Device for Percutaneous Intervention in Native Coronary Arteries.
Microembolization of particulate debris during percutaneous coronary intervention (PCI) will lead to various degree
of microvascular obstruction, terminating in no-reflow phenomenon observed angiographically. Different methods,
including angiography, non-invasive imaging, and assays of myocardial injury markers, have been used for detection
of occurrence of microvascular obstruction. The prevalence of, and the adverse prognosis associated with
microvascular obstruction have led to the concept and application of distal protection for coronary interventions.
While its value has been confirmed in saphenous vein grafts intervention, data is now growing to support use of
distal protection devices in native coronaries. Findings from a local registry that reveals the initial experience on
use of GuardWire Plus System, a kind of occlusive distal protection device, for elective PCI are discussed herein.
(J HK Coll Cardiol 2002;10:191-197)
Distal protection, microembolization, microvascular obstruction, percutaneous coronary intervention

PCI

GuardWire Plus

–

PCI

Introduction
Microembolization, Microvascular Obstruction
and No-Reflow: Pathophysiology
With the advances seen in various devices used
for percutaneous coronary intervention (PCI) and the
widespread use of stents, acute complications are
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uncommon during the procedure. However, slow distal
flow or no-reflow phenomena remain one of the
frustrations facing interventional cardiologists. The
pathophysiology underlying such phenomena seen
during PCI is likely to be complex, but probably starts
off with microembolization of particulate debris
dislodged from atherosclerotic/thrombotic lesions down
to distal capillary bed, causing microvascular
obstruction. 1 This in turn results in microvascular
plugging, microvascular spasm or edema, and/or platelet
aggregation. Experiments in canine models had shown
that embolization of a coronary artery with minute
particles/microspheres measuring less than 100 µm
resulted in regional contractile dysfunction and
perfusion-contraction mismatch. 2 Following
microvascular obstruction, epicardial flow is initially
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maintained or even enhanced due to an adenosinerelated hyperaemia of the myocardium surrounding the
embolized microregions, with blood shunting around
the areas of microvascular obstruction.1 However, as
the total embolized burdens increase, the epicardial flow
will eventually become reduced, corresponding to the
angiographic manifestation of slow distal flow or noreflow. In other words, no-reflow represents an
advanced stage of significant degree of microvascular
obstruction.

Detection of Microembolization and
Microvascular Obstruction
The presence and extent of microvascular
obstruction can be assessed by examining the degree of
impairment of myocardial perfusion. Several methods
have been used for this purpose. The angiographic
method is perhaps the simplest way in the
catheterization laboratory. Two different approaches
have been derived: first, to record the Corrected TIMI
Frame Count (CTFC) which is defined as the number
of cine frames required for contrast to first reach distal
coronary landmarks in that artery;3 and second, to report
on the TIMI Myocardial Perfusion (TMP) Grades (03) by noting the appearance of blush, and the rate at
which the blush disappears (Figure 1).4 Myocardial
contrast echocardiography constitutes another method

TMP Grade 3
Normal
ground-glass
appearance of
blush. Contrast
mildly persistent at
end of washout

TMP Grade 2
Contrast strongly
persistent at end of
washout. Disappears
by next injection

for assessing myocardial perfusion by intravenous or
intracoronary injection of sonicated bubbles. Ito et al5
showed that myocardial perfusion defects was
detectable in up to 26% of patients who had TIMI 3
flow in the infarct-related artery after reperfusion
therapy (either thrombolysis or primary angioplasty).
Nuclear imaging using Sestamibi Single-Photon
Emission Computerized Tomography (SPECT) has also
been used for detection of myocardial perfusion defects.
Koch et al6 demonstrated that up to 87% of patients
undergoing rotational atherectomy had detectable
perfusion defects on SPECT, but the figure dropped to
33% with infusion of abciximab, thereby providing
evidence that platelet emboli were at least partly
involved. Magnetic Resonance Imaging (MRI), on the
other hand, is able to demonstrate subendocardial
microvascular obstruction by showing regions of
hypoenhancement after contrast injection.7 Finally,
reduction in relative coronary flow velocity reserve (as
measured by intracoronary Doppler flow analysis) after
successful coronary intervention has been observed, and
has been related to microvascular obstruction.8,9
Abnormal levels of myocardial injury markers
represent the sequelae (when other confounding factors
like acute closure during the procedure or jailing of sidebranch are absent), and also serve as circumstantial
evidence for occurrence of microvascular obstruction
during PCI. In a study by Hong et al10 recording successful,

TMP Grade 1
Stain present. Blush
persists on next
injection

TMP Grade 0
No or minimal
blush

Figure 1. TIMI Myocardial Perfusion (TMP) Grades (Graphics supplied by Medtronic Inc.).
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angiographically and clinically uncomplicated PCI in
over 700 patients with saphenous vein graft (SVG)
lesions, raised creatine kinase-MB fraction (CK-MB)
levels, defined as levels above upper normal limit, were
detected in 38.5% of patients. In a recent study which
measured serum troponin T and I levels after successful
uncomplicated elective PCI in native coronary arteries,
up to 14% of patients had raised troponin T or I levels
in absence of side-branch occlusion.11 More evidence
to suggest microembolization during PCI comes from
the observation of a higher incidence of microvascular
obstruction associated with more aggressive coronary
intervention. Directional atherectomy, for instance, was
the strongest correlate of post-procedure CK-MB
elevation in a series of patients who underwent
successful PCI (odds ratio 4.1 when compared to balloon
angioplasty).12 The paradoxical finding of a decrease in
TIMI 3 flow in patients after stenting as compared to
balloon angioplasty in the Primary Angioplasty in
Myocardial Infarction (PAMI) trial lends more support
to the occurrence of microembolization.13

Impact of Microvascular Obstruction
on Outcomes Post-PCI
It is well known that occurrence of no-reflow
during PCI is associated with higher incidence of major
adverse cardiac events (MACE). In a study addressing
this issue, the incidences of non-Q myocardial infarction
and in-hospital mortality were reported as 31% and 15%
respectively.14 Even when epicardial flow is preserved,
the occurrence of microvascular obstruction will lead
to a worse outcome. In a study which recruited patients
with normal or mildly raised (<2 times upper limit of
normal) creatine kinase after successful PCI,
Abdelmeguid et al12 showed that the subgroups with
elevated CK-MB carried a higher incidence of MACE
over a median follow-up period of 3 years. Hong et al10
in the study on SVG interventions showed that the
1-year mortality rate in patients with post-procedure
CK-MB 1-5 times upper limit of normal and those with
CK-MB more than 5 times normal were, respectively,
at least 2 times and 4 times higher than patients with
normal CK-MB levels. In another study, Stone et al15
discovered that only 29.4% of patients who had TIMI 3
flow in the infarct-related artery after primary
angioplasty achieved a TMP Grade of 3. More
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importantly, the 1-year mortality rates in this group of
patients were closely correlated to the TMP Grades:
6.8% for TMP Grade 3; 13.2% for TMP Grade 2; and
up to 18.3% for TMP Grade 0/1.

Distal Protection for PCI
Distal Protection Devices
It is therefore reasonable to hypothesize that
protecting distal vessels from particulate embolization
can improve immediate and long-term outcome after
PCI. Different distal protection devices have been
designed. As of today, they fall into one of two
categories: a) distal occlusion balloon on a wire; any
particulate debris within the column of occluded blood
will be aspirated after intervention on target lesion; and
b) filter that can be deployed distal to target lesion,
trapping any particulate debris; the filter with the
entrapped debris are then retrieved with a capture sheath.
The former, as exemplified by the GuardWire Plus
System (Medtronic®) (Figure 2), has the advantages
of having a low crossing profile and completeness of
debris retrieval, but vessel occlusion is inevitable during
the procedure. The latter, as exemplified by the
AngioGuard Emboli Capture Guidewire (Cordis®)
(Figure 3) and the EPI FilterWire (Boston Scientific®)
(Figure 4) have the advantages of allowing continued
blood flow during the procedure, but suffer from having
a larger crossing profile (4.0F or more) and uncertainties
in offering complete protection or retrieval of entrapped
particulates.

Figure 2. The GuardWire Plus System (Medtronic®).
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patients, an improvement in TIMI 3 flow from 0% to
96% of patients was noted post-intervention using the
same GuardWire System,18 with 54.5% of patients who
had TIMI 3 flow achieving TMP Grade 3. Though
randomized comparison was not available, this 54.5%
of TMP Grade 3 was a significant improvement over
the 18.8% figure obtained from historical trial data. In
96% of this cohort, either thrombus or atherosclerotic
materials were successfully aspirated.
Figure 3. The AngioGuard Emboli Capture
Guidewire (Cordis®).

Use of Distal Protection for Elective PCI in
Native Coronary Arteries

Figure 4. The EPI FilterWire (Boston
Scientific®).

Clinical Data on Use of Distal Protection for PCI
The value of distal protection has been/is being
tested in two high-risk areas for microembolization:
interventions in saphenous vein grafts and on culprit
lesions of acute coronary syndromes. The SAFER trial16
is the first randomized clinical trial examining the
benefit of distal protection using GuardWire System
(Medtronic®) during interventions in SVG. Over 800
patients were enrolled in the trial. The incidence of noreflow was 3.4% using distal protection versus 8.8%
without distal protection. Incidences of in-hospital
MACE and 30-day MACE were decreased by 38% and
42% respectively with the use of distal protection. In
the setting of intervention for acute ST elevation
myocardial infarction (STEMI), a multicentre registry
in Europe recorded in 37 patients an improvement in
TIMI 3 flow from 24.3% to 86.1% and improvement in
TMP Grade 3 from 2.7% to 58.8% of patients postintervention with the use of GuardWire System. 17
Similarly, in a single-centre cohort of 51 STEMI
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Slow distal flow or no-reflow does occur
occasionally in the setting of elective PCI (excluding
interventions during acute phase of acute coronary
syndromes). In a review on all elective PCI in native
coronary arteries conducted in the authors'
catheterization laboratory in year 2001, the incidence
of slow distal flow/no-reflow was up to 3% when vessels
≥3.5 mm in diameter were counted, and up to 13% in
vessels ≥4.0 mm in diameter. As from deduction and
also from observation, larger plaque burden and more
friable plaque predispose to occurrence of such adverse
phenomena. However, there is as yet little controlled
data on the use of distal protection for elective PCI in
native coronary arteries. A recent report from Grube et
al19 included the experience of using the AngioGuard
Emboli Capture Guidewire (Cordis®) for distal
protection in 15 native coronary lesions. Particles
retrieved from the filters were sent for histochemical
staining, and the study constitutes "the first direct
evidence that embolization of arterial plaque
components occurs routinely during native coronary
artery interventions".

Local Registry on Use of Distal Protection for
Elective PCI in Native Coronaries
In view of the potential value of distal protection
for elective PCI in native coronaries, a registry on the
use of GuardWire Plus System (an improved version
of the original GuardWire System) has been set up in
the authors' hospital. Lesions included are those within
large native coronary arteries (≥3.5 mm), or lesions with
heavy plaque load/complex morphology/overlying
thrombus in coronary arteries ≥3.0 mm. Exclusion
criteria are: a) the presence of significant (≥1.5 mm)
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side-branch between the target lesion and potential
location of distal protection balloon on the GuardWire
(as otherwise most of the dislodged particulates may
embolize down the side-branch); b) diameter of distal
vessel segment where protection balloon would be
inflated is <3.0 mm; c) planned use of adjunctive devices
other than coronary stents, which would lengthen the
procedure and also the occlusion time; and d) anticipated
difficult stenting procedure (e.g. proximal calcified
segment or excessive proximal tortuosity), as the
protection balloon is usually only positioned 20-40 mm
distal to the lesion, and support from the GuardWire is
not as good as ordinary coronary wires. The first three
exclusion criteria are specific to the GuardWire Plus
System, and serve to illustrate that each protection
system available in market bears its own characteristics
and limitations. Two or three operators co-operated in
using the system. Basically the procedure can be divided
into 4 parts (Figure 5): a) passing the GuardWire across
the lesion and inflating the distal protection balloon; b)
performing intervention on the lesion as is required; c)
aspirating any particulate debris which may be present
in the column of occluded blood; and d) deflating the
distal protection balloon. In cases of tight lesions or in

A

totally occluded vessels, an ordinary coronary guidewire
may be used to cross the lesion first (as "buddy" wire),
with or without gentle predilatation with a small
diameter balloon to allow subsequent passage of the
GuardWire. Three different strategies could be
employed for target lesion intervention, depending on
coronary anatomy and expected patient's tolerance on
vessel occlusion during distal protection: a) direct
stenting; b) balloon angioplasty followed by an interim
period of rest before stenting (referred here as balloonrest-stent); c) combined balloon angioplasty and stenting
(balloon+stent) without interruption.
So far, distal protection for elective PCI in native
coronaries has been performed for 20 lesions in 17
patients (Table 1). Majority of the lesions were in RCA,
as expected because of the large size of this vessel often
encountered (Table 2).
Predilatation for initial passage of the GuardWire
was required only in 3 lesions. In fact, with more
experience in manipulating the GuardWire and in the
presence of good guiding catheter support, it is possible
to pass it through critical lesions without the need for
predilatation. Direct stenting was performed on
11 lesions; balloon-rest-stent on 7 lesions; and

B

C

D

Figure 5. Use of the GuardWire Plus System in a SVG is illustrated. (A) Crossing the lesion with the GuardWire. (B) Performing
intervention on target lesion while distal protection balloon is inflated. (C) Aspirating particulate debris through the aspiration
catheter. (D) Deflating the distal protection balloon.
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Table 1. Patients undergoing distal protection for
elective PCI
Total no.
M:F ratio
Mean age (yrs)
Indication for PCI
Stable angina
Stabilized after recent ACS

17
14:3
65.9±11.7
10
7

Table 2. Lesion characteristics
Vessel
RCA
LCx
LAD
Mean vessel size (mm)
Lesion type
A
B1
B2
C
Mean % stenosis

15
3
2
3.56±0.36
3
11
11
6
87.4±9.6

balloon+stent on 2 lesions. Mean vessel occlusion time
was 181 seconds for stenting in direct stenting and
balloon-rest-stent; 182 seconds for balloon angioplasty
during balloon-rest-stent; and 354 seconds for
balloon+stent. There is definitely a learning curve in
using the system. The mean occlusion time for stenting
in the last 5 lesions, for instance, has dropped to 146

seconds. The incidence of chest pain during distal
protection occurred in about half of patients, bradycardia
and BP drop (>20 mmHg from baseline) in around 60%
and 50% respectively; and ST segment changes in about
90%. All these symptom and changes disappeared on
relief of the vessel occlusion. Distal protection was
successfully performed for all lesions. TIMI 3 flow and
TMP Grade 3 were noted in every case. Amount of
plaque debris retrieved was recorded in a semiquantitative manner: small, moderate, and large. In
around two-thirds of instances, the amount retrieved
was either moderate or large (Figure 6). In none of the
cases was the yield negative. Problems encountered
were: one dissection at site of distal protection balloon
caused by over-sizing, handled by stenting; one incident
of initial difficulty in retracting the GuardWire due to
the protection balloon impinging on stent struts; and
one incident of non-deflating protection balloon,
handled by cutting the GuardWire. The first two
problems could have been avoided by more careful use,
while the last problem is reportedly rare according to
manufacturer. There was no in-hospital MACE related
to the use of distal protection. It thus appears that distal
protection using GuardWire Plus System for elective
PCI in native coronaries is a feasible option. The
successful retrieval in virtually all cases of particulate
debris which would otherwise have embolized down
the distal (micro) vasculature reflected the system's
efficacy in providing myocardial protection. Indeed, the
system has probably avoided several incidents of
adverse slow flow/no-reflow phenomenon, judging

Figure 6. Plaque debris retrieved.
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from the large size of the debris retrieved in some cases.
Whether these benefits would transcribe into better
clinical outcome would require confirmation by
randomized studies. On the other hand, there is
definitely a learning curve in the use of the device.
Operators are expected to encounter problems in their
early experience, and should be prepared to overcome
them if they do occur. In fact, with careful use and
as experience grows, most problems can be avoided.
It should be emphasized, however, that as the benefitrisk ratio is comparatively lower in the setting
of elective PCI than in PCI for acute coronary
syndromes, proper case selection, as well as
acquaintance with and proper use of the system are
important issues.

Conclusion
Evidences are now growing in support for distal
protection during PCI in native coronary arteries. Wellcontrolled randomized studies may eventually confirm
its clinical value, just as in the case of intervention in
saphenous vein grafts, especially in the area of primary
angioplasty for STEMI. In the setting of elective PCI
in native coronaries, further studies are required
to identify lesions that are prone to distal
microembolization in order to justify its use. With distal
protection devices becoming user-friendlier, they may
one day turn into a frequently used gadget that will help
prevent adverse consequences secondary to particulate
embolization that cannot be effectively prevented or
handled by pharmacological means.
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Is Dynamic Atrial Overdrive Pacing Antiarrhythmic or
Proarrhythmic: A Case Report
NGAI-YIN CHAN, MIU-FONG KWOK, CHI-CHUNG CHOY
From Cardiology Team, Department of Medicine and Geriatrics, Princess Margaret Hospital, Hong Kong
CHAN ET AL.: Is Dynamic Atrial Overdrive Pacing Antiarrhythmic or Proarrhythmic: A Case Report. Dynamic
atrial overdrive (DAO) pacing algorithm is designed for prevention of atrial arrhythmias, specifically atrial fibrillation
(AF). We describe a patient who underwent implantation of a dual chamber pacemaker with DAO function, for sinus
node dysfunction, paroxysmal AF and supraventricular tachycardia. The patient developed persistent high rate
pacing alternating with a long RP tachycardia, which was maintained by the DAO pacing algorithm. Sinus rhythm
resumed on turning off the DAO pacing. (J HK Coll Cardiol 2002;10:198-202)
Dynamic atrial overdrive, proarrhythmia
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Introduction
Dynamic atrial overdrive (DAO) is a recently
described pacing algorithm for prevention of atrial
arrhythmias, specifically atrial fibrillation (AF). 1-3
Stabile2 found that DAO pacing markedly reduced AF
recurrences in a group of 47 patients who had both
paroxysmal AF and indications for permanent cardiac
pacing. DAO pacing algorithm is designed to maintain
continuous atrial pacing. This is accomplished by
continual monitoring of the atrial rate and promptly

increasing the pacing rate when intrinsic rhythm
emerges. The pacing rate is reduced periodically to
search for atrial activity and inappropriately rapid pacing
is avoided. Possible mechanisms of its effectiveness
include prevention of bradycardia, reduction of
intraatrial conduction times and reduction of intraatrial
dispersion of refractoriness.4
DAO pacing is therefore supposed to be
antiarrhythmic. A case of supraventricular tachycardia
(SVT) maintained by DAO pacing is reported here. To
the best of the author's knowledge, this is the first case
report describing a possible proarrhythmic effect of
DAO pacing.
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Case Report
A 90-year-old woman was referred to our unit
for consideration of permanent cardiac pacing. She has
history of hypertension and had one episode of syncope
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6 years ago. She also complained of on and off fast
palpitation and dizziness. 24 hours Holter monitoring
revealed evidence of sinus node dysfunction with pauses
of 2 seconds and frequent episodes of supraventricular
tachycardia and atrial fibrillation. After obtaining
consent from the patient, permanent pacemaker
implantation was arranged.
A dual chamber pacemaker with DAO pacing
algorithm was chosen. SVT occurred during the
procedure both spontaneously and during pacing leads
manipulation. It was a long RP tachycardia with rate of
136/min (Figure 1). The P waves were negative in
inferior leads. The arrhythmia could only be terminated
transiently with intravenous adenosine (Figure 1), atrial
or ventricular overdrive pacing. The patient was
haemodynamically stable during SVT and the procedure
was successful with atrial and ventricular leads placed
at right atrial appendage and right ventricular apex
respectively. Echocardiogram performed after the
procedure revealed satisfactory left ventricular systolic

function. In view of the advanced age, electrophysiology
study and radiofrequency ablation of the arrhythmia is
not preferred. Verapamil 80 mg thrice daily was started
for prevention of SVT. DAO pacing was turned on for
paroxysmal AF. The maximum pacing rate was set at
150/min and the search interval was set at 8 cycles. This
setting will allow the V-A interval to be lengthened by
8 ms (DAO rate recovery for all rates) when there are 8
consecutive atrial paced beats. This new V-A interval
is used until either an intrinsic atrial sensed event occurs
and the algorithm shortens the V-A interval by 8 ms
(overdrive rate for all rates), or the end of the next search
interval of 8 cycles and the V-A interval is again
increased by 8 ms.
However, the patient developed persistent high
rate sequential atrioventricular pacing 120-130/min after
pacemaker implantation. A recurring pattern of
sequential atrioventricular pacing followed by several
beats of long RP tachycardia and then sequential
atrioventricular pacing again was observed (Figure 2).

Figure 1. Long RP tachycardia during pacemaker implantation. Negative P waves are well seen in inferior leads. The tachycardia
was terminated by intravenous adenosine and recurred spontaneously. There is prolongation of tachycardia cycle length with
increasing PR interval just before termination. The tachycardia ends with a P wave. Atrial tachycardia is unlikely with these
features.
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Intravenous adenosine or verapamil failed to terminate
this recurring pattern. Verapamil was then stopped and
Amiodarone was given. An intravenous loading dose
of 200 mg was given, followed by maintenance dose of
600 mg per day for two days and 720 mg per day for
another two days. However, same pattern of arrhythmia
persisted. On reviewing the recurring and alternating
pattern of high rate pacing and long RP tachycardia,
the following mechanism was postulated. As shown in
Figure 2, the unusual behaviour of DAO mechanism
that allows high rate sequential atrioventricular pacing,
in this case of rate around 110/min, served to induce
the long RP tachycardia. The rate of the tachycardia
induced was around 125/min. With the sensed atrial
activity during SVT, the V-A interval was gradually
shortened according to the DAO pacing algorithm.
Sequential atrioventricular pacing at a rate faster than
the SVT was then resumed and the SVT was terminated.
The V-A interval was then gradually lengthened
according to the DAO pacing algorithm and SVT was
then induced with a slower pacing rate. This pattern
was actually maintained by the DAO pacing algorithm

and the easily inducible SVT.
The DAO pacing function was turned off. The
arrhythmia subsided immediately and sinus rhythm was
resumed (Figure 3). Amiodarone 200 mg once per day
was continued for prevention of both paroxysmal AF
and SVT. The patient has been followed up for seven
months and there has been no clinical recurrence of SVT
or AF. 24 hour Holter monitoring did not reveal AF,
SVT or persistent high rate pacing.

Discussion
This patient has a long RP tachycardia.
Differential diagnoses include atrial tachycardia,
permanent form of junctional reciprocating tachycardia
(PJRT) and atypical atrioventricular nodal reentrant
tachycardia (AVNRT). The SVT was terminated
transiently with intravenous adenosine and the cycle
length also varied with the PR interval just before
termination (Figure 1). The SVT ended with a P wave.
Atrial tachycardia is unlikely with these features. And

Figure 2. Incessant high rate sequential atrioventricular pacing alternating with long RP tachycardia. Pacing rate was increased
gradually by the dynamic atrial overdrive (DAO) pacing algorithm in response to the long RP tachycardia. The tachycardia was
then terminated and high rate sequential atrioventricular pacing remained. The DAO pacing algorithm allows the pacing rate to
decrease gradually and at the point indicated by the arrow, a retrograde P wave followed by the same long RP tachycardia was
induced. This pattern of arrhythmia has been recurring for days since pacemaker implantation.
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Figure 3. Sinus rhythm immediately resumed after turning off of the dynamic atrial overdrive pacing.

possibilities therefore include PJRT and atypical
AVNRT. Because of the advanced age of this patient,
electrophysiology study was not performed and the
definitive diagnosis cannot be made.
Spontaneous PJRT initiation and induction
during electrophysiology study usually occur after
only trivial increases in sinus rate or atrial overdrive
pacing. 5 The exact mechanism is not known. One
likely mechanism is a concealed Wenckebach-type
block at the atrial-bypass tract junction. The block
relieves any antegrade concealed conduction that may
have prevented retrograde conduction up the bypass
tract. 6 An orthodromic atrioventricular reentrant
tachycardia is then facilitated. In this case, the fact
that the SVT, which is a long RP tachycardia, is
readily initiated spontaneously or by atrial overdrive
pacing above the sinus rate, favours the diagnosis of
PJRT. With the active DAO pacing algorithm, the
pacing rate is gradually increased until it is faster
than the SVT which is then terminated. The same
pacing algorithm allows the pacing rate to drop
gradually and at some point, the SVT will be induced
again. This pattern becomes persistent and is
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maintained by the DAO pacing algorithm and the
easily inducible SVT. The remote possibility of
persistent SVT even during high rate pacing is highly
unlikely. It will require some form of "entrainment"
during sequential atrioventricular pacing. This is
difficult, if not impossible, to achieve. On the other
hand, the fact that sinus rhythm immediately resumed
after turning off DAO pacing argues against the
mechanism of persistent SVT even during high rate
pacing. Effect of Amiodarone also cannot explain the
immediate response to the turning off of DAO pacing.
Although DAO pacing is designed to be
antiarrhythmic in atrial arrhythmias, specifically
atrial fibrillation, it can be proarrhythmic. Persistent
high rate pacing may result especially in patients with
SVT which is easily initiated spontaneously or
induced by atrial overdrive pacing just above the
sinus rate. Definitive treatment with
electrophysiology study and radiofrequency ablation
can confirm the diagnosis and eliminate the substrate
for arrhythmia. However, when invasive procedure
is not preferred as in this patient, the DAO pacing
algorithm may have to be turned off.
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ECG Quiz
TSE-FUN LAM
From Department of Medicine, Kwong Wah Hospital, Kowloon, Hong Kong

A 76-year-old shopkeeper presented to
Emergency Department (ED) with a minor forehead
laceration sustained at work. He was sitting at the
cashier when he experienced a faint and landed on
left side of his body. He denied any chest symptom
before the event and regained full consciousness upon
reaching the floor. He did experience on and off
giddiness in the past few days. He was not taking any
medication, either recently or in the long term. Family

history was negative of any significant medical
illness.
He had a prior admission to another hospital
one year ago for fever and cough, and was
incidentally found to have bradycardia. He defaulted
follow-up since then, as he was not symptomatic
from it.
Figure 1 showed the ECG performed at ED.
What was the cause of his syncope?

Figure 1.
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Answer
The presenting ECG showed a sinus rate of 65/
min and a ventricular rate of 38/min. There was
complete atrio-ventricular dissociation. The QT
interval was markedly prolonged, most prominent in
lead V6. The corrected QTc interval was definitely
excessive.
The presence of bradycardia and profoundly
long QT raised the suspicion of Torsade de Pointes
(TdP) as the underlying mechanism of syncope. TdP
is a type of polymorphic ventricular tachycardia with
continuous phasic alteration of the QRS morphology.
It was first described by Desertenne in 1966.
Figure 2 was an ECG captured after the patient
arrived at the ward. It illustrated the onset of
polymorphic ventricular tachycardias initiated by a
timed premature ventricular coupling (PVC) on the

terminal end of a QT after a long cycle. This "longshort" phenomenon together with the underlying
bradycardia and QT prolongation are the three key
points to TdP.
QT prolongation-TdP couple can be congenital
or acquired. Common acquired causes include antiarrhythmic agents, phenothiazines, tricyclic antidepressants and various anti-microbial agents.
Profound bradycardia and electrolyte disturbance
such as hypokaelemia and hypomagnesemia can also
result in QT prolongation and precipitate TdP.
Management of this gentleman depends on the
accurate diagnosis and correction of the underlying
cause for the QT prolongation. Together with the
correction of the reversible elements such as
electrolyte disturbance, temporary overdrive pacing
should be contemplated to prevent inappropriately
firing PVC and thus achieving rate regularization.

Figure 2.
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